1	A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for
2	the treatment of post kala-azar dermal leishmaniasis.
3	
4	Brima M. Younis <sup>1</sup> , Rebecca Wiggins <sup>2</sup> , Eltahir A.G. Khalil <sup>1</sup> , Mohamed Osman <sup>2</sup> , Francesco
5	Santoro <sup>3</sup> , Chiara Sonnati <sup>3</sup> , Ada Keding <sup>4</sup> , Maria Novedrati <sup>3</sup> , Giorgio Montesi <sup>3</sup> , Ali
6	Noureldein <sup>1</sup> , Elmukashfi T. A. Elmukashfi <sup>1</sup> , Ala Eldin Mustafa <sup>1</sup> , Mohammed Alamin <sup>1</sup> ,
7	Mohammed Saeed <sup>1</sup> , Khalid Salman <sup>1</sup> , Ahmed J. Suliman <sup>1</sup> , Amin E.A. Musa <sup>1</sup> , Alison M.
8	Layton <sup>2</sup> , Charles J. N. Lacey <sup>2*</sup> , Paul M. Kaye <sup>2*§</sup> and Ahmed M. Musa <sup>1*§</sup> .
9	
10	<sup>1</sup> Department of Clinical Pathology & Immunology, Institute of Endemic Diseases, University
11	of Khartoum, Sudan
12	<sup>2</sup> York Biomedical Research Institute, Hull York Medical School, University of York,
13	Heslington, York, UK
14	<sup>3</sup> Department of Medical Biotechnologies, University of Siena, Siena, Italy
15	<sup>4</sup> Department of Health Sciences, University of York, Heslington, York, UK
16	
17	* These authors contributed equally to the work
18	<sup>§</sup> Correspondence should be addressed to PMK ( <u>paul.kaye@york.ac.uk</u> ) or AMM
19	(ahmed.musa@uofk.edu)
20	
21	Short title: Phase IIb leishmaniasis vaccine trial.
22	
23	Key words: Leishmania, post kala azar dermal leishmaniasis, vaccine, therapeutic,
24	adenovirus, clinical trial.
25	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 26 Summary

Background. In a recent Phase IIa clinical trial, the candidate leishmaniasis vaccine
ChAd63-KH was shown to be safe and immunogenic in Sudanese patients with post kalaazar dermal leishmaniasis (PKDL). However, its value as a stand-alone therapeutic was
unknown.

Methods. To assess the therapeutic efficacy of ChAd63-KH, we conducted a "window of 31 opportunity" randomized, double-blind, placebo-controlled trial (Clinicaltrials.gov 32 registration: NCT03969134). We aimed to enrol 100 participants (male and female aged 12-33 50 years) with uncomplicated PKDL of > six months duration. ChAd63-KH (7.5x10<sup>10</sup> viral 34 35 particles) or saline placebo was administered once intramuscularly. Primary outcomes were safety and efficacy. Safety was determined by adverse event monitoring. Efficacy was the 36 37 proportion of participants at 90 days post-vaccination with  $\geq$ 90% improvement in clinical disease. Participants failing to reach this clinical endpoint were offered a standard of care 38 39 (AmBisome<sup>®</sup>). Secondary outcomes included changes in PKDL severity grade and 40 measurements of vaccine-induced immune response.

Findings. Between 4<sup>th</sup> April 2020 and 17<sup>th</sup> June 2022, 86 participants (66 adolescents, 20 41 42 adults; 47% female, 53% male) were enrolled and randomised to receive ChAd63-KH or placebo. 75 participants (87%) completed the trial as per protocol. No severe or serious 43 adverse events were observed. At day 90 post vaccination, 6/40 (15%) and 4/35 (11%) 44 45 participants in the vaccine and placebo groups respectively showed  $\geq 90\%$  clinical improvement (RR 1.31 [95% CI, 0.40 to 4.28], p=0.742). There were also no significant 46 47 differences in PKDL grade between study arms. Whole blood transcriptomic analysis identified transcriptional modules associated with interferon responses and monocyte and 48 49 dendritic cell activation, confirming vaccine reactogenicity.

50	Interpretation. Single dose administration of ChAd63-KH vaccine had no therapeutic			
51	efficacy in this subset of Sudanese PKDL patients. Further studies are needed to evaluate			
52	whether this vaccine would have therapeutic benefit using alternate dosing regimens or in			
53	combination with standard chemotherapy or immune modulation, and whether it has efficacy			
54	as a prophylactic vaccine for cutaneous or visceral leishmaniasis.			
55	Funding. This study was funded by the Wellcome Trust.			
56				
57	Research in context			
58	Evidence before this study.			
59	A leishmaniasis vaccine candidate was developed employing chimpanzee adenovirus 63			
60	(ChAd63) to deliver genes encoding two Leishmania antigens, KMP-11 and HASPB1. This			
61	vaccine (ChAd63-KH) was previously evaluated for safety and immunogenicity in a Phase I			
62	healthy volunteer study and a Phase IIa study in Sudanese patients with post kala-azar dermal			
63	leishmaniasis (PKDL). It was shown to be safe and immunogenic, warranting further clinical			
64	studies to evaluate efficacy as a stand-alone therapeutic in PKDL patients.			
65	Added value of this study.			
66	This clinical trial was designed to evaluate the safety and efficacy of ChAd63-KH in PKDL			
67	patients with persistent disease (dermal lesions for $\geq 6$ months). If successful, single dose			
68	vaccination would significantly improve treatment options currently available to patients.			
69	The safety of ChAd63-KH was confirmed, with no severe or serious adverse events observed			
70	in trial participants. Approximately 13% of participants had $\geq$ 90% improvement in their			

- 71 PKDL over the course of 90 days follow up post vaccination, but this did not differ between
- vaccine and placebo arms, indicating that this reflected spontaneous cure rather than vaccine

range of the previous of the p

reported ability of this vaccine to induce immune responses in humans.

### 75 Implications of all the available evidence.

76 This study indicates that as a stand-alone treatment, single dose vaccination with ChAd63-

- 77 KH was unable to overcome the immune dysfunction that maintains persistent PKDL. A
- similar "high bar" has also been encountered in therapeutic vaccine trials for other persistent
- 79 diseases. Given previous success with other forms of immunochemotherapy in PKDL, future
- 80 therapeutic vaccine studies in PKDL might also benefit from combining ChAd63-KH
- 81 vaccination with additional chemotherapy or immune modulation. The prophylactic efficacy
- 82 of this vaccine against different types of leishmaniasis also remains to be evaluated.
- 83
- 84

# 85 Introduction

Post kala azar dermal leishmaniasis (PKDL) is a chronic dermatological sequela associated 86 87 with treatment for visceral leishmaniasis (VL; kala azar), but it may occur without a history 88 of VL or even during treatment of VL (when it is known as para kala-azar dermal leishmaniasis). PKDL typically involves the face and later spreads to the extremities and 89 90 trunk <sup>1-3</sup>. PKDL has often been confused with leprosy and because of its chronic but not debilitating nature, it is often tolerated by infected people who fail to seek treatment. Case 91 92 rates for PKDL are intimately linked to the waxing and waning of VL incidence<sup>4</sup>. The VL elimination campaign in South Asia has served to focus attention on PKDL, as those with the 93 disease have been shown to harbour parasites in their skin and be infectious to the sand fly 94 95 vector. As such, people with PKDL may serve to maintain infection in inter-epidemic periods thus posing a threat to elimination<sup>5</sup>. Epidemiological modelling has demonstrated the value 96 of a PKDL vaccine for mitigating this risk in a post-elimination era <sup>6</sup>. Recent calls to action 97

for VL elimination on the African continent also recognise the need to have effective means
to control PKDL <sup>7</sup>. Drug regimens for PKDL are generally arduous, invasive and have
multiple potential side effects <sup>8,9</sup>. PKDL can also be exacerbated by HIV, and such cases
respond poorly to treatment <sup>10</sup>. New combination therapies have been evaluated and show
promise both in reducing the burden of PKDL <sup>11</sup> and in treatment <sup>12</sup>, but there has been a
strong and persistent argument for developing additional means of control including
therapeutic vaccines <sup>13-15</sup>.

105

106 PKDL has several intriguing features epidemiologically, clinically and immunologically. VL is caused by infection with two species of the protozoan parasite *Leishmania*, namely L. 107 donovani and L. infantum, yet PKDL is restricted to infection with L. donovani and found 108 109 only in the Old World <sup>2</sup>. PKDL is also restricted within the geographical range of L. donovani, being found in Sudan and South Asia, but rarely in other countries in East Africa. 110 111 PKDL typically occurs after treatment whether this be with pentavalent antimonials, amphotericin B, miltefosine and paromomycin/ antimonial combinations <sup>16</sup>. However, the 112 113 onset of disease varies geographically, being rapid (weeks to months) in Sudan compared to 114 delayed (often years) in South Asia. Clinical presentation also varies geographically and at different body sites, with various hypotheses, including UVB exposure, being put forward to 115 explain differences in clinical presentation <sup>17,18</sup>. In Sudan, disease presents mainly as nodules 116 and papules that in  $\sim 80\%$  of cases self-resolve over several months  $^{8,19}$ . In the remainder, 117 lesions may persist often for years. In contrast, in South Asia cases can show hypopigmented 118 macular lesions or be polymorphic, with both macular and nodular lesions. Immunological 119 and histopathological differences have also been noted <sup>17,18,20-23</sup>. Collectively, these features 120 suggest that PKDL is a heterogeneous disease, with implications for the development of new 121 122 therapeutics.

123 Therapeutic vaccination against PKDL in Sudan has its historical roots in the use of firstgeneration vaccines for VL. Khalil and colleagues conducted Phase I/II randomised trials in 124 125 volunteers with no history of VL and showed that two intradermal doses of autoclaved L. major (ALM) administered with Bacille Calmette-Guérin (BCG) was safe, well tolerated and 126 immunogenic, as measured by skin test conversion <sup>24-26</sup>. However, no efficacy with regards 127 protection against VL was observed. These studies were followed up by evaluation of alum-128 129 adjuvanted ALM + BCG, again demonstrating safety and immunogenicity  $^{27,28}$ . This latter formulation was subsequently evaluated as a potential therapeutic in PKDL patients with 130 131 persistent disease. The study enrolled 30 patients randomised to receive Alum-ALM+BCG + sodium stibogluconate (SSG) vs. SSG alone and reported a cure rate at 60 days of 87% in the 132 combined therapy group vs 53% in the SSG alone group (SSG + vaccine efficacy=71%, 95%) 133 134 CI for risk ratio (0.7-1.16))<sup>29</sup>. Based on these encouraging results, we evaluated the safety and immunogenicity of ChAd63-KH, a new adenoviral vaccine incorporating two well-135 136 documented vaccine candidate antigens that was designed to have potential as a panleishmaniasis vaccine <sup>30</sup>. This open label Phase IIa therapeutic trial in persistent PKDL 137 patients (LEISH2a; ClinicalTrials.gov ID: NCT02894008) was designed as a "window of 138 139 opportunity" study, where vaccine was administered alone, and standard of care provided as needed after a 90 day follow up period <sup>31</sup>. The study confirmed that ChAd63-KH was both 140 safe and immunogenic in this patient group, opening the way for the randomised controlled 141 142 efficacy trial reported here. 143

144

145 Methods

146 *Ethics statement* 

147	The LEISH2b study (Clinicaltrials.gov ID: NCT03969134) was approved by the Sudan
148	National Medicines and Poisons Board, and the Ethical Review Committees of the Institute
149	of Endemic Diseases, University of Khartoum and the Department of Biology, University of
150	York. LEISH2b was sponsored by the University of York. The study was conducted
151	according to the principles of the current revision of the Declaration of Helsinki 2008 and
152	ICH guidelines for GCP (CPMP/ICH/135/95). All participants provided written informed
153	consent before enrolment. Consent forms are available accompanying the published protocol
154	32

155

156 Study design and participants

LEISH2b was a randomized, double blind, placebo-controlled therapeutic trial designed to 157 158 evaluate the safety and efficacy of therapeutic vaccination with the investigational vaccine ChAd63-KH. The initial study design allowed for recruitment of 100 participants diagnosed 159 160 with PKDL aged between 18-50 (adults) or 12-17 (adolescents) and with persistent PKDL of greater than six months duration. Full details of the inclusion and exclusion criteria are 161 provided in the published Protocol <sup>32</sup>. Participants were recruited from an endemic area in 162 163 Gedaref state, Sudan and all study procedures were conducted at the Professor El-Hassan's Centre for Tropical Medicine, Dooka, Sudan. Clinical monitoring of the study was 164 performed under contract by ClinServ (http://www.clinserv.net). An independent Data Safety 165 166 and Monitoring Board (DSMB) was established and met throughout the study period. The DSMB Charter is available accompanying the published protocol <sup>32</sup>. 167 168 169 Eligibility criteria

170 Full inclusion and exclusion criteria are provided in the Protocol <sup>32</sup>. Key inclusion criteria

171 included: age 12 to 50 years on the day of screening; females must be unmarried, single, or

172 widowed; willing and able to give written informed consent/assent; uncomplicated PKDL of > six month duration; otherwise good health; negative for malaria on blood smear; 173 174 Leishmania PCR positive on the screening skin biopsy; willing to undergo urinary pregnancy tests (females only). Key exclusion criteria included: mucosal or conjunctival PKDL; 175 treatment for PKDL within 21 days: negative rK39 strip test; receipt of a live attenuated 176 177 vaccine within 60 days or other vaccine within 14 days of screening; history of allergic disease or reactions to vaccines or their components; history of severe local or general 178 reaction to vaccination; fever  $\geq$  39.5°C within 48 hours, anaphylaxis, bronchospasm, 179 180 laryngeal oedema, collapse, convulsions or encephalopathy within 48 hours; pregnancy, less than 12 weeks postpartum, lactating, or willingness/intention to become pregnant during the 181 study and for three months following vaccination (females only); seropositive for hepatitis B 182 183 surface antigen (HBsAg) or Hepatitis C (antibodies to HCV); tuberculosis, leprosy, or malnutrition (malnutrition in adults defined as a BMI <18.5, and in children and adolescents 184 185 (eight-17yrs) as a Z score cut-off value of <-2 SD).

186

#### 187 *Vaccine and study procedures*

188 As described previously<sup>31</sup>, ChAd63-KH encodes two leishmanial proteins (KMP-11 and

189 HASPB1) and was manufactured to cGMP by Advent Srl. (Pomezia, Italy; lot B0004;

190  $7.5 \times 10^{10}$  viral particles (vp) per ml). ChAd63-KH was administered as a single dose in 1ml

volume intramuscularly into the deltoid muscle. Participants were monitored in hospital for 7

days post vaccination and thereafter as out-patients on days 21, 42, 90 and 120 post

193 vaccination. Recruitment occurred over four rounds, punctuated by a revolution, a pandemic

- and a coup. Meetings of the independent DSMB were held at the end of each round of
- 195 recruitment. Participants were evaluated for clinical response at day 42 and day 90. Those
- 196 with less than 75% improvement at day 90 were offered standard treatment (AmBisome<sup>®</sup>;

2.5mg/kg/day for 20 days). If improvement was between 75-90%, they were offered
conservative treatment or AmBisome®, and those with greater than or equal to 90% clinical
improvement were deemed to not require further treatment (and scored as clinical cure).
Some participants defaulted from scheduled visits and were evaluated and treated at
unscheduled visits based on their availability. Decisions to treat and evaluation of PKDL
were performed by two clinicians. Clinical grade of PKDL was also recorded before and
after vaccination using the 4-point grading system described previously <sup>33</sup>.

204

## 205 Randomisation and Blinding

A computer generated (Stata 16) randomisation list was prepared by the trial statistician, 206 allocating participants 1:1 to either the active or placebo injection, using randomly permuted 207 208 blocks, stratified by age group (adult or adolescent). The randomisation allocation was 209 communicated to pharmacy staff at the study site through pre-prepared, sealed envelopes 210 with only external sequential participant numbers. During the trial, adults were found to be more difficult to recruit, and the initial aim of an equal number of adolescents and adults in 211 212 the trial was not feasible. However, the number of available randomisation envelopes in the 213 Sudan was limited for each age group. Therefore, once allocations for the adolescent group had been used up, allocations for the adult stratum were used in order of presentation 214 215 irrespective of age group, thus creating a single, unstratified randomised sample.

216

The vaccine and placebo injections were prepared in blacked out syringes labelled only with the participant identification number. The participants and clinical investigators (who administered the IMP and conducted the study follow-up) were blinded as to which injection participants received. The trial statistician (who generated the randomisation list), trial coordinator (who prepared sealed envelopes according to the randomisation list), assistant

pharmacist (who prepared the IMP) and study nurse (who delivered the IMP to the clinicalinvestigators) were not blind to the treatment allocation.

- 224
- 225 *Outcomes*

Primary outcome measures were i) safety as recorded as adverse events from clinical 226 227 examination and evaluation of blood biochemistry and haematology, and ii) efficacy, as determined by the proportion of participants reaching  $\geq 90\%$  improvement in clinical disease. 228 229 Secondary outcomes included trajectory of lesion improvement and measures of vaccine 230 induced immune response. Planned immune analyses included whole blood transcriptomics 231 and analysis of peripheral lymphocyte responses (Ab and IFNy ELISpot). Peripheral 232 lymphocyte and antibody responses could not be measured due to sample loss resulting from 233 the military conflict in Sudan.

234

### 235 Statistical analysis

236 The statistical analysis plan is provided in the Supplementary Data file. A total sample size of 100 (randomly assigned 1:1 to be vaccinated with ChAd63-KH or placebo) was 237 determined to be sufficient to detect an increase of >25% in the proportion of participants 238 239 achieving clinical cure, assuming 90% power, 5% statistical significance, a spontaneous clearance rate of  $\leq 2\%$  and loss to follow-up of  $\leq 5\%$  (Fisher's exact test). Baseline 240 241 characteristics were summarised descriptively. Continuous measures are reported as mean, 242 standard deviation, median, and range while categorical data are reported as counts and 243 percentages. Number of local and systemic AEs per participant are presented as median, 244 minimum, maximum and IQR. The median number of AEs per participant (separately for local and systemic events) were compared between groups using the Mann-Whitney U test. 245 246 Primary efficacy outcome of >90% clinical improvement between the two arms was

evaluated using relative risk ratio (RR) with statistical significance determined by Fisher's
Exact Test. Event numbers were too low to allow for an adjusted regression analysis.
Comparison of categorical data across groups was analysed using Fisher's Exact Test.
Analyses were performed using Stata v18, Rv4.3.2 or Prism 10 for macOS (v10.1.1;
GraphPad).

252

253 Whole blood transcriptomic analysis

Whole blood samples (2.5 ml) were collected into PAXgene tubes immediately prior to 254 255 vaccination and at 1 day post vaccination. All reagents and equipment for these analyses were supplied by ThermoFisher Scientific and processes carried out per manufacturers' protocols, 256 257 unless otherwise stated. Total RNA was extracted using the PAXgene Blood RNA kit 258 (PreAnalytiX, QIAGEN). RNA was quantified using the Qubit® 2.0 Fluorometer with the RNA HS Assay Kit. ~50 ng of total RNA was used to construct sequencing libraries with the 259 260 Ion AmpliSeq<sup>™</sup> Transcriptome Human Gene Expression Kit. Libraries were barcoded, 261 purified with 2.5 X Agencourt AMPure XP Magnetic Beads (Beckman Coulter) and then 262 quantified using Ion Library TaqMan Quantitation Kit on a QuantStudio 5. Libraries were 263 diluted to a concentration of about 50 pMol and pooled in groups of 8 for sequencing on Ion PI Chips. Chips were loaded using the Ion Chef System and the IonPI Hi-Q Chef Kit. 264 265 Sequencing was performed on an Ion Proton Sequencer using Ion PI Hi-Q Sequencing 200 266 Kit.

267

Differential gene expression analysis was performed using DeSeq2. After count data
normalization, differential gene expression analysis was performed using pooled day 0 data
from the two study cohorts as the baseline for all contrasts. Enrichment of blood transcription
modules at each time point in the different groups was assessed with the tmod R package,

272	using as an input the lists of differentially expressed genes ranked by the p-value after
273	multiple test correction, as computed by DeSeq2. Significance of module enrichment was
274	assessed using the CERNO statistical test (a modification of Fisher's combined probability
275	test) and corrected for multiple testing using the Benjamini-Hochberg correction.
276	
277	Role of Funders
278	The funders played no part in study design, data collection, analysis, interpretation, writing or
279	decision to publish. All authors had full access to study data and final responsibility for the
280	decision to submit for publication.
281	
282	
283	Results
284	Site Initiation and recruitment
285	The LEISH2b study was conducted over approximately four years, punctuated by periods of
286	significant challenge that resulted in temporary trial suspensions. The site initiation visit
287	(SIV), attended by all field site personnel, trial monitors and trial staff from the Universities
288	of Khartoum and York took place in August 2019 in Addis Ababa, due to a popular uprising
289	and deteriorating security situation in Sudan. Recruitment began on 4th April 2020 and
290	continued through June 2020 with 17 participants recruited in this period. Recruitment was
291	then paused due to the SARS-CoV-2 pandemic. The second round of recruitment took place
292	between December 2020 and February 2021, enrolling 28 participants. A third round of
293	recruitment took place in April and May 2021 adding 23 participants. Delayed by a military
294	coup, the final round of recruitment (May to June 2022) added 18 more, bringing the total to
295	86 participants. Following discussion with the LEISH2b DSMB, a meeting of the Trial
296	Steering Group with the funders was convened. All attendees agreed that recruitment should

297 halt at 86 participants due to logistical difficulties in completing the trial prior to expiry of the IMP and with the onset of further military clashes. 75/86 (87%) of enrolled participants 298 299 completed the study to day 90 post vaccination, with last patient, last visit on 20th Sept 2022. 300 Missed visits and losses to follow up were due to occupational priorities. A further day 120 visit was arranged to allow follow up of any drug treatment provided at the completion of the 301 302 study. A summary of study recruitment is provided in the CONSORT diagram (Figure 1). 303 304 Study population Demographics and PKDL grading of the 86 participants enrolled in this study are shown in 305 306 **Table 1**. All participants had PKDL for 6mths duration or longer with the majority (88%) 307 graded as either PKDL grade 1 or 2 (Table 1 and Table S1). Day 90 visits were completed 308 by 75 (87%) participants (n=11missed this time point or had been lost to follow-up; Figure 309 1). As per protocol, participants were offered standard of care (AmBisome®) at day 90 if clinical improvement was less than 90%. Overall, 26/86 (30%) elected to receive treatment 310

311 (8/20 adults; 18/66 adolescents) and these participants remain in long term follow up to312 confirm drug effectiveness.

313

314 *Safety outcomes* 

There were 70 (25 local and 45 systemic) AEs reported by 43 participants during the study split 1.6:1 between vaccine and placebo groups (**Tables S2-S5**). Average number of local AEs per participant were 0.30 in the vaccine vs 0.29 in the placebo arm (median of 0 in both arms), and systemic AEs per participant were 0.68 in the vaccine vs 0.36 in the placebo arm (median of 0 in both arms). Event numbers did not significantly differ between arms (Mann-Whitney U p =0.921 and p=0.501 respectively). AEs were limited to grade 1 and 2, with no grade 3, SAEs or SUSARs reported. All local and systemic AEs were deemed to be not

322	serious and recovered. 44 AEs (25 local and 19 systemic) were considered possibly-,
323	probably-, or definitely related to vaccination again showing a bias towards vaccine
324	recipients (Figure 2). These included itch, pain or soft swelling at the injection site,
325	headache, vomiting, fever and general muscle pain. Medication was not required for any of
326	the local AEs but paracetamol (for headache, chills, fever) and chlorphenamine (for whole
327	body itch) were prescribed for systemic AEs. No clinically relevant changes in blood
328	biochemistry or haematology were observed. The most common systemic AE unrelated to the
329	study was malaria (16 clinical episodes, 15 patients). One case of thrombocytopenia was
330	recorded but deemed unrelated to vaccination (occurring in the placebo group).
331	
332	Clinical outcomes
333	The per protocol primary outcome measure was 90% or greater improvement in clinical
334	PKDL as determined by two clinical assessors. Of the 75 participants that completed the
335	study to d90 (39F, 36M; Table S1), 6/40 (15%; 2F, 4M) and 4/35 (11%; 3F, 1M) in the
336	vaccine and placebo arms respectively reached this threshold (RR 1.31 [95% CI, 0.40 to
337	4.28], p=0.742). To explore whether there was any vaccine effect at lower levels of
338	improvement, we calculated the proportion of participants that attained 25, 50, 75 and 90% of
339	improvement over time of follow up, and the trajectory of recovery appeared very similar
340	between arms (Figure 3a). Of note, all participants that reached the primary outcome did so
341	between day 42 and d90 of follow up. The secondary outcome of PKDL grading (Grade 1 to
342	Grade 4) was evaluated as PKDL severity is often used to monitor disease status <sup>33</sup> . Grade
343	distributions improved only marginally over time and were similar between arms (p = $0.36$ ,
344	p=0.53 and $p=0.38$ for days 21, 42 and 90 respectively; Fisher's exact test; Figure 3b).
345	

346	As duration of PKDL has been suggested to influence cure rate <sup>19</sup> , we additionally obtained
347	prior duration in months data for a sub-group of 57/75 participants completing day 90 FU (45
348	adolescents, 12 adults; 33F, 24M). We stratified this subgroup into two classes based on
349	duration of PKDL (<18 mths: median 11 months, range 6-11 months; $n = 26$ and $\ge 18$ mths,
350	median 36 months, range 18 - 120 months, $n=31$ ) and evaluated whether there was any
351	difference in the proportion of patients reaching a conservative 50% improvement. In the
352	<18 mths duration class, 6/11 receiving vaccine and 6/15 receiving placebo reached this
353	threshold compared to $5/19$ and $5/12$ in the >18 mths duration class. Hence, duration of
354	PKDL in this limited cohort did not appear to be associated with vaccine response or overall
355	improvement.
356	
357	Collectively, these analyses indicate that under the trial conditions employed, ChAd63-KH
358	lacked efficacy as a single treatment in patients with persistent PKDL in Sudan.
359	
360	Whole blood transcriptome prior to and after vaccination
361	We used whole blood transcriptional analysis (WBTA) to confirm vaccine reactogenicity and
362	capacity to induce immune responses in a subset of patients ( $n=23$ placebo and $n=27$ Vx) for
363	which PAXgene-collected blood samples were available for analysis. Compared to pre-
364	vaccination, no differentially expressed genes (DEGs) were identified at day 1 post
365	vaccination in patients receiving placebo (log2FC >1, adj p<0.05). In contrast in patients
366	receiving ChAd63-KH, we identified 318 DEGs using this threshold (311 UP, 7 DOWN;
367	Table S6). Using g-profiler, we annotated enriched terms associated with the response to
368	ChAd63-KH, providing clear evidence of anti-viral, inflammatory, and immune response
369	gene activation (Figure 4a and Table S6). To provide comparison with data from our
370	previous Phase IIa study and responses to a range of other vaccines <sup>36</sup> , we next identified

371	transcriptional modules associated with vaccination <sup>37</sup> . In keeping with the above analysis
372	and with our previous analysis of ChAd63-KH responsiveness in PKDL patients <sup>31</sup> , highly
373	upregulated transcriptional modules included those associated with interferon responsiveness,
374	dendritic cell and monocyte activation and antigen presentation (Figure 4b and Table S6).
375	Out of 57 significantly enriched transcriptional modules, 31 were also enriched in the
376	adolescent cohort of the LEISH2a study <sup>31</sup> . Given that only 2/50 of the patients for which
377	transcriptomic data was available achieved the primary outcome of $\geq$ 90% clinical response, it
378	was not possible to conduct a robust analysis to identify differentially expressed genes or
379	modules associated with clinical cure.
380	
381	
382	Discussion
383	ChAd63-KH is a "third generation" DNA vaccine based on adenoviral delivery of a gene
384	construct encoding two well-characterised Leishmania antigens. In a Phase IIb stand-alone
385	therapeutic trial in Sudanese patients with persistent PKDL, we have confirmed safety of this
386	vaccine. However, this study failed to demonstrate clinical efficacy when measured by
387	clearance of PKDL lesions over a 90-day follow up period.
388	
389	The study was conducted in Gedaref state, South-eastern Sudan against a backdrop of
390	significant adversity. Over the study period, Sudan sequentially experienced a revolution, a
391	pandemic, a coup and military conflict that remains ongoing to date. Nevertheless,
392	throughout this period, the trial team were able to maintain most aspects of trial management
393	and governance although considerable delays in recruitment and in the ability to undertake
394	sample analysis occurred. Following consultation with the DSMB and trial sponsor, the
395	decision was taken in November 2022 to curtail recruitment at 86 participants, short of the

396	100 originally proposed. Full data analysis for the primary clinical outcome is reported here,
397	with additional sub-group analysis being reported where patient metadata or biological
398	samples were incomplete (either due to sample loss or data inaccessibility).

399

400 The primary clinical outcome of the study was to determine whether a single administration 401 of ChAd63-KH vaccine was able to induce  $\geq$ 90% improvement of PKDL in Sudanese 402 patients with persistent disease of > 6 months duration. Our analysis of 75 patients that that 403 completed follow up to day 90 indicated that this was not the case. Similarly, PKDL grade 404 was not improved over this time in vaccinated patients compared to those receiving placebo. 405 Relaxing the criterion for clinical response also did not reveal any significant vaccine effect or effect of duration of prior PKDL. Hence, we conclude that this Phase IIb clinical trial has 406 407 not demonstrated efficacy of ChAd63-KH under the conditions tested.

408

409 It is therefore important to consider the premise on which this study was based and potential 410 reasons why efficacy was not observed. The immunopathogenic mechanisms that result in 411 the chronic dermal presentation of PKDL are not fully understood. Immunohistological 412 analysis of biopsies from Sudanese PKDL patients have noted the presence of CD4<sup>+</sup> and 413 CD8<sup>+</sup> T cells but their functional state has not been characterised. Granuloma formation is 414 seen in some cases but the histopathological picture may not correspond with clinical outcome <sup>23</sup>. Keratinocyte IL-10 expression during VL was observed to be associated with 415 later development of PKDL <sup>36</sup>, but the specific role of IL-10 in PKDL per se is not 416 417 understood. In Indian PKDL, more extensive studies have characterised CCR4<sup>+</sup>CD8<sup>+</sup> T cells with a phenotype associated with exhaustion and immune regulation (PD-1<sup>hi</sup> IL-10<sup>+</sup>) <sup>20</sup>. 418 419 Collectively, these findings lend support to the hypothesis underpinning this trial i.e. that 420 enhancing CD8<sup>+</sup> T cell activation through vaccination may augment the ability of the host to

421 clear parasites/antigens and reduce local pathology. Although we were unable to study 422 antigen specific T cell responses in this study due to loss of all frozen cells, our previous studies have indicated that KMP-11- and HASPB-specific CD8<sup>+</sup> IFN $\gamma^+$  responses are induced 423 in PKDL patients <sup>31</sup> and healthy volunteers <sup>30</sup> following ChAd63-KH vaccination. Given the 424 comparability of the transcriptional response to vaccination seen in this and our other studies. 425 we have no reason to suspect that similar T cell responses were not induced in this patient 426 group. However, in the absence of efficacy, it is difficult to ascertain whether this CD8<sup>+</sup>T 427 428 cell response was merely insufficient in magnitude to elicit a clinical response or whether a broader response (in terms of antigen specificity or immune response quality) might be 429 430 needed to achieve a clinical response.

431

With their known ability to rapidly induce antigen specific CD8<sup>+</sup> T cells, adenoviral vectored 432 433 vaccines have been extensively studied as potential therapeutic vaccines in cancer and chronic hepatitis B virus (HBV) infection. However, studies in these other diseases have to 434 date also met with limited success. Whilst poor choice of immunogens was previously 435 436 mooted as the explanation for therapeutic failure in cancer therapeutic trials, a common 437 attribute of cancer and chronic viral disease is the development of a microenvironment that 438 favours immune regulation or suppression. These changes often reflect the outcome of 439 signalling through inhibitory checkpoint pathways (e.g. PD-1) or the induction of metabolic 440 checkpoints such as IDO1, and it has been proposed that these disease-associated regulatory constraints on T cell function hinder vaccine efficacy. Experimental evidence to support this 441 notion has been provided by Maini and colleagues who identified both NK cell and PD-1/PD-442 L1 signalling as negative regulators of HBV vaccine efficacy in animals <sup>37</sup>. Whilst evidence 443 444 for such an immunoregulatory environment is less well established in PKDL and other forms 445 of dermal leishmaniasis, some similarities to these other chronic diseases exist. For example,

446 both IDO1 and PD-L1 are abundant in chronic cutaneous leishmaniasis lesions resulting from L. donovani infection in Sri Lanka, with a reduction in PD-L1 expression predicting rate of 447 cure after antimonial chemotherapy <sup>38</sup>. More recently, we have identified expression of these 448 449 checkpoint molecules in CL patients infected with L. (V.) braziliensis and also in PKDL patients infected with L. donovani in India <sup>39</sup>. PKDL lesions are also enriched in M2 450 macrophages <sup>21</sup> contributing to a lack of leishmanicidal capacity and an immunoregulatory 451 452 environment. Hence, it is possible that the local inhibitory environment in the skin of persistent PKDL patients provides an obstacle to effector CD8<sup>+</sup> T cell function at this site. If 453 454 this is indeed the case, it is likely that therapeutic vaccination in PKDL might also benefit from interventions that target regulatory pathways, such as those proposed in HBV <sup>37</sup>. Whilst 455 studies using existing biologics or other clinically approved drugs might provide proof of 456 457 concept data in PKDL, it is recognised that such high-cost adjunct therapies are unlikely to drive vaccine implementation in a lower- and middle-income country (LMIC) setting. 458 459 Alternatively, vaccination in conjunction with anti-leishmanial chemotherapy should also be considered, given previous successes with immunochemotherapy in PKDL<sup>29</sup> and more recent 460 evidence suggesting that such chemotherapy may also diminish the immunoregulatory 461 environment in CL patients<sup>38</sup>. 462

463

We confirm in this study the potent ability of ChAd63-KH to induce innate responses characterised by antiviral gene signatures and dendritic cell and monocyte activation, with weaker representation of modules associated with neutrophil response and complement activation. The modules signatures observed are also in keeping with those observed in a multi-vaccine analysis conducted by Hagan et al <sup>40</sup> which included an adenoviral vaccine candidate (MRKAd5-HIV) and with our previous analysis of PKDL patients <sup>31</sup>. In the latter study, we observed that adolescents but not adults differentially expressed modules associated

with B cell activation (M47.0 and M47.1). However, we did not observe differential 471 expression these modules in the current study, despite the patient subgroup studied for WBTA 472 473 being mainly composed of adolescents. The reasons for this difference are currently unknown and are subject to ongoing investigation. We had also previously identified 11 474 whole blood transcriptional modules predictive of 90% clinical cure, two of which were 475 476 significantly differentially expressed between cure and non-cure participants (M139: lysosomal/endosomal proteins and M118.0: enriched in monocytes). Unfortunately, as only 477 478 2/50 of the samples analysed here achieved this level of clinical cure, we are unable to 479 confirm or otherwise the predictive value of these modules. 480

481 In addition to the loss of samples / data due to the ongoing conflict in Sudan and other issues 482 discussed above, a limitation in study design was the evaluation of only one vaccination schedule. ChAd63-KH was administered as a stand-alone therapy using a single dose given 483 484 intramuscularly. This approach was chosen for both scientific and pragmatic reasons. Extensive data derived from experimental studies and early phase human trials <sup>41</sup> and from 485 late phase trials and real world evidence obtained during the SARS-CoV-2 pandemic<sup>42</sup> have 486 487 indicated that repeat dosing with homologous adenovirus vaccines fails to significantly augment the CD8<sup>+</sup> T cell response. Though direct evidence is lacking, it seems likely that a 488 489 similar outcome would occur with vaccination in PKDL patients. Pragmatically, single dose 490 schedules have multiple benefits in a LMIC setting, including reducing logistical 491 complexities and a reduction in cost, not least due to the savings from not requiring manufacture of two clinical grade vaccines. Similarly, intramuscular dosing is preferred in 492 493 many clinical situations due to ease of administration and standardisation and tolerability but may not be the most appropriate route for eliciting skin homing CD8<sup>+</sup> T cells <sup>43</sup>. Thus, we 494 cannot rule out that an efficacy signal may have been observed using a repeat dosing 495

496	schedule, by extending the period of follow up, by use of a heterologous prime-boost strategy
497	$^{41}$ and / or by varying route of administration. Given the heterogeneity of clinical
498	presentation and histopathology observed in PKDL, our data do not rule out the possibility of
499	a therapeutic benefit from ChAd63-KH vaccination in either Sudanese patients with less
500	persistent disease or in PKDL patients in South Asia. In addition, the prophylactic efficacy of
501	this vaccine against different types of leishmaniasis remains to be evaluated. In conclusion,
502	however, this Phase IIb study did not provide evidence to support progressing ChAd63-KH
503	as a standalone therapeutic in Sudanese patients with persistent PKDL.
504	
505	
506	Contributors
507	Conceptualisation by EAGK, PMK, AML, CJNL, AMM and BMY. Clinical studies were
508	conducted by BMY, EAGK, MO, AN, ETAE, A-AM, AJS, AMM, MA, ME, KS, and AEAM.
509	Trial data collation and analysis was conducted by AK, RW, AMM, AML, CJNL, and PMK.
510	Transcriptomic analysis was conducted by FS, CS, MN, GM, and PMK. Statistical analysis
511	was conducted by AK and PMK. Writing original draft by PMK. Review & editing draft by
512	CJNL, AML, AMM, BMY, RW and AK. Writing final draft by PMK. All authors read and
513	approved the final version of the manuscript.
514	
515	Declaration of Interests
516	PMK and CJNL are co-inventors of a patent that covers the gene insert used in ChAd63-KH.
517	No other conflicts of interest are declared.
518	

519 Acknowledgments

520	The clinical trial was funded by a Wellcome Trust Translation Award (WT108518MA;				
521	https://wellcome.ac.uk). Additional support for transcriptomics studies was provided by a				
522	Wellcome Trust Senior Investigator Award (to PMK; WT104726) and by the TRANSVAC2				
523	program supported by the European Union's Horizon 2020 Research and Innovation				
524	programme under grant agreement No. 730964 (TNA1802-02; https://www.transvac.org).				
525	GSK is allowing York University to use the cell line ProCell92 (proprietary of GSK) for their				
526	adeno program. GSK had the opportunity to review the publication, but the content is solely				
527	the responsibility of the authors. The authors also express their gratitude to the DSMB (Dr				
528	Rob Davidson, Dr Koert Ritmeijer, Dr Wolfgang Stohr, and Prof Alaadin Ahmed) for their				
529	advice, continual support and encouragement and to all the study participants and their				
530	families.				
531					
532	Data Sharing Statement				
533	Processed gene expression data are available as supplementary material. Raw gene				
534	expression data will be available from GEO on publication.				
535					
536					
537	References				
538 539 540 541 542 543 544	<ol> <li>Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> 2001; 95</li> <li>Suppl 1: S59-76.</li> <li>Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. <i>The Lancet infectious diseases</i> 2003; 3(2): 87-98.</li> <li>Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar dermal leishmaniasisan overview. <i>International journal of dermatology</i> 2010; 49(8): 921-31.</li> </ol>				

- 545 4. Saurabh S, Roy P, Pandey DK, et al. Changing clinico-epidemiology of post-kala-azar
  546 dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states. *J Vector*547 *Borne Dis* 2020; 57(2): 161-9.
- 548 5. Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in
  549 the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination
- 550 Programme. *PLoS Negl Trop Dis* 2017; **11**(11): e0005877.

551 6. Le Rutte EA, Coffeng LE, Malvolti S, Kaye PM, de Vlas SJ. The potential impact of 552 human visceral leishmaniasis vaccines on population incidence. PLoS neglected tropical diseases 2020; 14(7): e0008468. 553 554 Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as 7. 555 a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. *Lancet Glob Health* 2021; 9(12): e1763-e9. 556 557 Musa AM, Khalil EA, Younis BM, et al. Treatment-based strategy for the 8. 558 management of post-kala-azar dermal leishmaniasis patients in the Sudan. Journal of tropical 559 medicine 2013; 2013: 708391. 560 Datta A, Podder I, Das A, Sil A, Das NK. Therapeutic Modalities in Post Kala-azar 9. 561 Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options. Indian J Dermatol 2021; 66(1): 34-43. 562 Zijlstra EE. PKDL and other dermal lesions in HIV co-infected patients with 563 10. 564 Leishmaniasis: review of clinical presentation in relation to immune responses. PLoS Negl 565 *Trop Dis* 2014; **8**(11): e3258. Musa AM, Mbui J, Mohammed R, et al. Paromomycin and Miltefosine Combination 566 11. 567 as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. Clin Infect Dis 2023; 76(3): e1177-e85. 568 Younis BM, Musa AM, Monnerat S, et al. Safety and efficacy of 569 12. 570 paromomycin/miltefosine/liposomal amphotericin B 2 combinations for the treatment of post-kala-azar dermal leishmaniasis in 571 572 3 Sudan: a phase II, open label, randomized, parallel arm study. *PLoSNTD* 2024; in press. 573 13. Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE. Report of the Post 574 Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012. Parasites & vectors 2013; 6: 196. 575 576 14. Ghalib H, Modabber F. Consultation meeting on the development of therapeutic 577 vaccines for post kala azar dermal leishmaniasis. *Kinetoplastid biology and disease* 2007; 6: 578 7. 579 15. Zijlstra EE, Kumar A, Sharma A, Rijal S, Mondal D, Routray S. Report of the Fifth 580 Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14-16 May 581 2018. Parasites & vectors 2020; 13(1): 159. 582 Das VN, Pandey K, Singh D, Forwood C, Lal CS, Das P. Development of post-kala-16. azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge 583 584 to elimination program in India. Journal of postgraduate medicine 2013; 59(3): 226-8. Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal 585 17. 586 leishmaniasis: an unresolved mystery. Trends in parasitology 2014; 30(2): 65-74. 587 18. Ismail A, Khalil EA, Musa AM, et al. The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a 588 589 role? Medical hypotheses 2006; 66(5): 993-9. Musa AM, Khalil EA, Raheem MA, et al. The natural history of Sudanese post-kala-590 19. 591 azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med 592 Parasitol 2002; 96(8): 765-72. 593 Mukherjee S, Sengupta R, Mukhopadhyay D, et al. Impaired activation of lesional 20. 594 CD8(+) T-cells is associated with enhanced expression of Programmed Death-1 in Indian 595 Post Kala-azar Dermal Leishmaniasis. Sci Rep 2019; 9(1): 762. 596 21. Mukhopadhyay D, Mukherjee S, Roy S, et al. M2 Polarization of Monocytes-597 Macrophages Is a Hallmark of Indian Post Kala-Azar Dermal Leishmaniasis. PLoS Negl Trop 598 Dis 2015; 9(10): e0004145. 599 Zijlstra EE. The immunology of post-kala-azar dermal leishmaniasis (PKDL). 22. 600 Parasites & vectors 2016; 9: 464.

601 23. Ramesh V, Ramam M. Histopathology of Post Kala-azar Dermal Leishmaniasis. 602 Indian J Dermatol 2020; 65(6): 461-4. Khalil EA, Elhassan AM, Zijlstra EE, et al. Safety and immunogenicity of an 603 24. 604 autoclaved Leishmania major vaccine. East Afr Med J 2000; 77(9): 468-70. 605 Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine 25. for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in 606 607 Sudan. Lancet 2000; 356(9241): 1565-9. 26. Satti IN, Osman HY, Daifalla NS, et al. Immunogenicity and safety of autoclaved 608 Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001; 19(15-609 610 16): 2100-6. Kamil AA, Khalil EA, Musa AM, et al. Alum-precipitated autoclaved Leishmania 611 27. major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, 612 skin-delayed type hypersensitivity response and dose finding in healthy volunteers. 613 614 Transactions of the Royal Society of Tropical Medicine and Hygiene 2003; 97(3): 365-8. 615 28. Khalil EA, Musa AM, Modabber F, El-Hassan AM. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major 616 617 + BCG) in children: an extended phase II study. Ann Trop Paediatr 2006; 26(4): 357-61. Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-618 29. kala-azar dermal leishmaniasis: a novel approach to treatment. Transactions of the Royal 619 620 Society of Tropical Medicine and Hygiene 2008: **102**(1): 58-63. Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral 621 30. 622 leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. 623 PLoS Negl Trop Dis 2017; 11(5): e0005527. 624 31. Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-625 KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther 2021; 29(7): 626 2366-77. 627 32. Lacey C, Musa A, Khalil ET, et al. LEISH2b - A phase 2b study to assess the safety, 628 efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis. Wellcome Open Res 2022; 7: 200. 629 630 33. Zijlstra EE, el-Hassan AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-631 azar dermal leishmaniasis. Am J Trop Med Hvg 1995; 52(4): 299-305. Therneau TM. A package for survival analysis in R. 2020. https://CRAN.R-632 34. 633 project.org/package=survival. Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing Survival Curves 634 35. using 'ggplot2'. https://cran.r-project.org/web/packages/survminer/index.html. 635 Gasim S, Elhassan AM, Khalil EA, et al. High levels of plasma IL-10 and expression 636 36. 637 of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998; 111(1): 64-9. 638 639 37. Maini MK. Tissue T cells in prophylactic and therapeutic vaccination responses. Semin Arthritis Rheum 2023; 63: 152287. 640 641 38. Dey NS, Senaratne S, Somaratne V, et al. Early reduction in PD-L1 expression 642 predicts faster treatment response in human cutaneous leishmaniasis. J Clin Invest 2021; 643 131(22). 39. 644 Dey NS, Dey S, Brown N, et al. IL-32 producing CD8<sup>+</sup> memory T cells 645 and Tregs define the IDO1 / PD-L1 niche in human cutaneous leishmaniasis skin lesions. medRxiv 2024: 2024.01.02.23300281. 646 40. Hagan T, Gerritsen B, Tomalin LE, et al. Transcriptional atlas of the human immune 647 648 response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.

649 *Nat Immunol* 2022; **23**(12): 1788-98.

- Hill AV, Reyes-Sandoval A, O'Hara G, et al. Prime-boost vectored malaria vaccines:
  progress and prospects. *Hum Vaccin* 2010; 6(1): 78-83.
- 42. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of
- 653 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults
- 654 (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* 2021; **396**(10267): 1979-93.
- 43. Rotrosen E, Kupper TS. Assessing the generation of tissue resident memory T cells by
- 657 vaccines. *Nat Rev Immunol* 2023; **23**(10): 655-65.

Characteri	stics	Vaccine		Placebo	
		N=44		N=42	
Adults		n=11		n=9	
		Ν	%	N	%
Sex	Male	8	73	6	67
	Female	3	27	3	33
PKDL grade	Grade 1	7	64	2	22
	Grade 2	3	27	5	56
	Grade 3	1	9	2	22
Age (years)	Mean (SD)	23.2 (	(5.98)	24.3 (7.18)	
	Median	2	1	22	
	Min, Max	18, 37		18,40	
BMI	Mean (SD)	19.8 (1.92)		20.4 (1.67)	
	Median	20	).1	19	9.6
	Min, Max	16.2, 23.1		18.8, 23.3	
Adolescents		n=33		n=33	
		Ν	%	N	%
Sex	Male	17	52	15	45
	Female	16	48	18	55
PKDL grade	Grade 1	14	42	18	55
	Grade 2	15	45	12	36
	Grade 3	4	12	3	9
Age (years)	Mean (SD)	13.4 (1.78)		13.0 (1.49)	
	Median	12		1	2
	Min, Max	12, 17		12,	17
BMI	Mean (SD)	17.2 (	17.2 (2.85)		(2.01)
	Median	16.9		15	5.9
	Min, Max	12.4,	26.9	12.9,	20.7

659 660

# 661 Table 1. Baseline characteristics of participants in Leish2b trial



## 698 Figure 1. Study CONSORT diagram

Solid boxes indicate participants to primary outcome at day 90 post vaccination. Treatment
was offered per protocol from d90 (see text). Dotted boxes were outside trial window for
primary outcome and represent scheduled follow to provide or monitor standard of care.



### 706 Figure 2 Adverse events associated with the LEISH2b trial.

Data are shown for local and systemic adverse events judged to be possibly, probably, likely,
or definitely associated with vaccination. Data are shown as proportion of participants in the
study (n=86). Only grade 1 AEs (mild, yellow; 26 vs. 17 events overall in vaccine vs placebo
group) and grade 2 AEs (moderate; orange; 17 vs. 10 events overall in vaccine vs. placebo
group) were observed. See Tables S2-S5 for full details.



## 742

741

## 743 Figure 3. Clinical improvement in LEISH2b participants

**a.** Clinical improvement by study arm (n = 40 and n = 35 for vaccine and placebo groups

respectively). Participants were categorised based on degree of improvement at different

times post vaccination (Vx). Colour key indicates improvement category. **b.** Distribution of

overall PKDL grades by study arm (n = 40 and n = 35 for vaccine and placebo groups

respectively). Participants were scored for PKDL grade at vaccination (day 0) and at

749 indicated days post vaccination (Vx). Colour key indicates grades. No significant differences

750 were detected at any time point or over time (Fisher's Exact test; see text).





752 753

# 754 Figure 4. Whole blood transcriptomic analysis of vaccine response

WBTA was conducted on blood drawn prior to and 1 day post vaccination. Data are shown

for 50 vaccinated participants (19F, 31M; 9 adults, 41 adolescents). a. gProfiler analysis of

- 757 311 upregulated genes. Representative enriched pathways are numbered: 1. GO:0003725,
- double stranded RNA binding; 2. GO:0001730, 2'-5'-oligoadenylate synthetase activity; 3.
- 759 GO:0042379, chemokine receptor binding; 4. GO:0019221, cytokine-mediated signalling
- pathway; 5. GO:0034097, response to cytokine; 6. GO:0045089, positive regulation of innate
- immune response; 7. GO:0051607, defence response to virus; 8. GO:0034341, response to
- type II interferon; 9. GO:0071357, cellular response to type I interferon; 10. REAC:R-HAS-
- 1, cytokine signalling in immune system; 11. TF:M00772, IRF motif,; 12. TF:M10080,
- 764 STAT2 motif. Full details are provided in Table S6. b. Significantly enriched immune-related
- modules were identified applying the CERNO test on the adjusted p value-ranked lists of
- genes generated by DeSeq2 (see Table S6 for module gene lists). Bars represent proportion of
- significantly upregulated (red), downregulated (blue) or unchanged (grey) genes. The
- significance of module activation is proportional to the intensity of the bar, while the effect
- size is proportional to its width. Only top 35 modules (of 57; see Table S6) are shown for clarity. No DEGs and hence no modules were identified in patients receiving placebo.

771	Supplementary information				
772	Supplementary Data				
773	The Supplementary Data_ Tables S2-S5 and SAP file contains the following:				
774	1. Table S2 List of AEs by body system and preferred term				
775	2. Table S3 List of AE severity by preferred term				
776	3. Table S4 List of non-serious AEs				
777	4. Table S5 List of vital signs and laboratory tests				
778	5. Leish2b statistical analysis plan (SAP)				
779					
780	Supplementary Data _Table S1				
781	This Excel file supports Figure 3 and contains the following:				
782	Raw data on PKDL improvement, prior PKDL duration, age, sex, subsequent treatment for				
783	all participants by coded ID.				
784					
785	Supplementary Data_Table S6				
786	This <i>Excel file</i> contains the following:				
787	1. Raw counts table for 50 patients measured at day 0 and day 1 post vaccination				
788	2. List of 311 upregulated genes in patients receiving ChAd63-KH (adj p<0.05; 2-fold				
789	change)				
790	3. List of 7 down regulated genes in patients receiving ChAd63-KH (adj p<0.05; 2-fold				
791	change)				
792	4. g-profiler output list of enriched terms for the 311 upregulated genes				
793	5. Transcriptional module gene list (after Li et al (Ref 36))				
794	6. Module analysis of response to ChAd63-KH				